Sexual health

PT-141

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as Bremelanotide

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

PT-141 is listed in the ezGLP knowledgebase under Sexual health. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category: Sexual health
Routes represented: Subcutaneous (SubQ)
Approximate library half-life: 2.7 hours; formulation-dependent and not dosing guidance
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Published literature

Safety evidence

Common or reported: nausea, flushing, injection-site reactions, headache, vomiting.

Serious or important: transient blood-pressure increase, heart-rate reduction, persistent focal hyperpigmentation.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With oral naltrexone

Safety flag

Bremelanotide substantially decreases oral naltrexone exposure and can cause treatment failure.

Interaction evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.